Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Inc.
• Treatments: Maleic acid; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Provide signed, written informed consent

• 18 yeas of age and older

• Diagnosed with primary open-angle glaucoma or ocular hypertension

• Female subject of childbearing potential must utilize reliable contraceptive throughout the study and have a negative urine pregnancy test prior to enrollment into this study

• Meet specific Visit 2, Day 0 (Baseline)criteria at baseline

Exclusion Criteria:

• Females who are pregnant, nursing or planning a pregnancy

• Presence of any abnormality or significant illness that could be expected to interfere with the study.